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Abstract
Background: Language support for linguistic minorities can improve patient safety, clinical outcomes and the
quality of health care. Most chronic hepatitis B/C infections in Europe are detected among people born in endemic
countries mostly in Africa, Asia and Central/Eastern Europe, groups that may experience language barriers when
accessing health care services in their host countries. We investigated availability of interpreters and translated
materials for linguistic minority hepatitis B/C patients. We also investigated clinicians’ agreement that language
barriers are explanations of three scenarios: the low screening uptake of hepatitis B/C screening, the lack of
screening in primary care, and why cases do not reach specialist care.
Methods: An online survey was developed, translated and sent to experts in five health care services involved in
screening or treating viral hepatitis in six European countries: Germany, Hungary, Italy, the Netherlands, Spain and the
United Kingdom (UK). The five areas of health care were: general practice/family medicine, antenatal care, health care for
asylum seekers, sexual health and specialist secondary care. We measured availability using a three-point ordinal scale
(‘very common’, ‘variable or not routine’ and ‘rarely or never’). We measured agreement using a five-point Likert scale.
Results: We received 238 responses (23% response rate, N = 1026) from representatives in each health care field in each
country. Interpreters are common in the UK, the Netherlands and Spain but variable or rare in Germany, Hungary and
Italy. Translated materials are rarely/never available in Hungary, Italy and Spain but commonly or variably available in the
Netherlands, Germany and the UK. Differing levels of agreement that language barriers explain the three scenarios are
seen across the countries. Professionals in countries with most infrequent availability (Hungary and Italy) disagree
strongest that language barriers are explanations.
Conclusions: Our findings show pronounced differences between countries in availability of interpreters, differences
that mirror socio-cultural value systems of ‘difference-sensitive’ and ‘difference-blindness’. Improved language support is
needed given the complex natural history of hepatitis B/C, the recognised barriers to screening and care, and the large
undiagnosed burden among (potentially) linguistic minority migrant groups.
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Background
Most chronic viral hepatitis infections in Europe are
detected among migrants born in countries with a
medium to high prevalence of hepatitis B and/or C [1].
This includes most of Africa and Asia, Central/Eastern
Europe and the countries of the former Soviet Union [2,
3]. Chronic viral hepatitis B (CHB) and C (CHC) infec-
tions have a complex natural history and could require
lifelong clinical monitoring and antiviral treatment [4].
People chronically infected with hepatitis B or C can
also remain infectious to others and should modify or
avoid certain behaviours that have a high risk of trans-
mission [5]. These features underline the need to pro-
vide patients with information and advice about the
implications of a diagnosis such as referral to specialist
secondary care, diagnostic tests required, the availability
of antiviral treatment, how to prevent onward transmis-
sion, contact tracing and HBV vaccination. However,
research suggests that many diagnosed patients do not
reach secondary care for clinical monitoring and anti-
viral treatment [6, 7], that language barriers are per-
ceived to be the primary barrier to health care for viral
hepatitis [8], and that immigration status is associated
with not receiving treatment [9]. The asymptomatic
nature as well as a lack of screening and suboptimal
referral strategies means that more than 60% of people
infected are unaware of their infection, undiagnosed and
not in treatment [1, 10, 11]. Effective antiviral treatment
for both chronic hepatitis B/C that can prevent the
development of cirrhosis and hepatocellular carcinoma,
and with newer direct acting anti-virals (DAAs) report-
ing cure rates in up to 90% of cases of chronic hepatitis
C, [12] the elimination of chronic viral hepatitis a possi-
bility in Europe [13]. This will require the continued
primary prevention of new infections alongside the
expansion of secondary prevention through screening
and treatment.
Language barriers between linguistic minority mi-
grants (migrants who face language barriers because
they do not speak the local language) and health care
professionals are reported to increase inequalities in
health care via adverse effects on accessibility, quality of
care, patient satisfaction, patient safety and patient
health outcomes [14]. A systematic review of medical in-
terpreter services in the United States (US) showed
negative health outcomes as well as poor knowledge and
understanding of diagnoses, treatment and implications
of the disease, among patients who needed but did not
have access to interpreter services, which resulted in
inaccurate medical history-taking and missed/incorrect
diagnoses [15]. Conversely, interpreters have been dem-
onstrated to have a positive impact both on clinical
outcomes and in reducing inequalities [16]. Thus, inter-
preters are deemed to be of benefit from both the
perspectives of social justice and of evidence-based clin-
ical medicine. Studies that examine good practice in
health care for migrants recommend the provision of in-
terpreters and/or translated materials to overcome lan-
guage barriers as a means to improve patients safety, the
quality of health care, medical ethical practice and
patient outcomes [16, 17]. Good practice studies of viral
hepatitis screening programmes among at-risk migrant
populations also provide translated materials and/or in-
terpreters to improve screening uptake, to reach more
vulnerable sub-populations (those with very limited local
language skills) and to raise awareness in communities
at risk [18–21].
There is a distinct lack of disease-specific research
however, and much of the literature about language bar-
riers is focused on the countries of the English speaking
world (the United States (US), Canada, the UK and
Australia) where language proficiency is defined as
limited English proficiency. We use ‘linguistic minority’
as a more appropriate term for our research in the Euro-
pean Union (EU), specifically in Germany, Hungary,
Italy, the Netherlands, Spain and the United Kingdom
(UK) These six European countries are the locations of
the academic and clinical teams participating in the
HEPscreen project from which this study arose ([http://
www.hepscreen.eu]). They also differ considerably in
their history and experience of migration as well as the
health system response to diversity. The proportion of the
adult population defined as foreign-born varies from 4.6%
in Hungary and 9.5% in Italy to more than 10% in the
Netherlands (11.5%), the UK (12.6%), Spain (13.2%) and
Germany (13.6%) [22, 23]. The UK, the Netherlands and
Spain have been described as having a ‘difference-based’
or communitarian approach to migration and diversity, by
recognising difference, actively adapting services to diver-
sity and providing tailored (as opposed to mainstream)
health care services [24]. The ‘difference-blind’ or ‘republi-
cation’ systems of Germany, Italy and Hungary assume all
citizens should be treated equally through the provision of
mainstream (as opposed to separatist) services that are
passive to diversity and operate with expectations of as-
similation by migrants [25]. The six study countries also
vary in regard to the financing available for health care.
For instance, Germany and the Netherlands spend around
five times the amount (per capita) on health care than
Hungary (4753.9 USD and 5456.5 USD (respectively) vs.
991.3 USD in 2012) [26].
It is likely that these differences in experience of
migration, of socio-cultural value system response to
diversity and in health care financing will affect the
availability of language support services in the six study
countries. In this exploratory study, we investigated the
availability of language support services (interpreters and
translated written materials about the virus/disease) for
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linguistic minority chronic viral hepatitis patients. We
also investigated health care professionals’ agreement
that language barriers are explanations of the lack of
hepatitis B/C screening among people born in medium/
high prevalence countries in primary care, the low
uptake of screening among these patients and why
people diagnosed with a chronic infection do not reach
specialist care. This study is part of HEPscreen ([http://
www.hepscreen.eu]), an EU Health Programme-funded
project generally focused on screening for chronic viral
hepatitis among migrants in Europe and specifically
focused on these six countries.
Methods
We developed an online survey and sent it to a large con-
venience sample (n = 1026) of expert clinicians involved in
screening or care for viral hepatitis in six EU countries:
Germany, Hungary, Italy, the Netherlands, Spain and the
UK (England, Wales and Scotland). Recipients were
identified via a comprehensive snowballing method via
stakeholder consultation within our HEPscreen project
consortium, and membership of professional networks or
clinical associations involved in five areas of health care:
general practice/family medicine, antenatal care, health
care for asylum seekers, sexual health services, and special-
ist secondary care. The aim was to reach knowledgeable
experts able to reflect on the circumstances in their profes-
sion and country rather than use a representative sampling
framework among individual clinicians. We took a health
system approach, looking across countries rather than
within specific health care services.
The survey measured availability of written and oral lan-
guage support services (translated materials and telephone
or face-to-face interpreters) using closed questions and a
three-point ordinal scale: ‘very common’, ‘variable or not
routinely’ and ‘rarely or never’ (unsure was also available).
We also measured clinicians’ perception, using three
closed questions and a five-point Likert scale of agree-
ment, of how far language barriers explain three scenarios:
the low uptake of screening for hepatitis B/C among mi-
grants born in medium/high prevalence countries; the
lack of screening by primary care services among migrants
with country of birth-related risk factors; and why people
diagnosed with a chronic infection do not reach specialist
care for further investigation and antiviral treatment.
These three scenarios respectively reflect patient-related,
health care service-related and health care system-related
issues. The questions reported here are specific sections of
a larger survey aimed at understanding screening, referral,
treatment and clinical management of hepatitis B/C pa-
tients in the six countries. Findings from other sections
will be and are reported elsewhere [27].
The survey was pre-tested five times in English in
three of the study countries, each with a professional
from each of the five professions/health care sectors:
from general practice (in Italy), an antenatal care (in
Germany), health care for asylum seekers (in Italy),
sexual health (in the Netherlands), and specialists in
hepatology/gastroenterology (in the Netherlands)). The
method used to pre-test was influenced by cognitive
interviewing techniques which allow for every detail, no
matter how trivial, to be captured by asking subjects to
‘think out loud’ about the question and answer options.
Interviewers can gauge how well the subject has inter-
preted and understood each aspect of the survey. These
techniques also allow for ambiguous or unfamiliar
terms and questions to be identified [28]. Feedback
from each interview was discussed within the research
team and a consensus was reached on each proposed
amendment or addition. Several minor changes were
made to each survey following pre-testing. Please see
the Additional files 1, 2, 3, 4 and 5 available online
for the final version of the survey.
A professional translation company was used to trans-
late the survey into the languages of the study countries.
To ensure the versions provided were understandable,
accurate and professional, a native speaker (and fluent
English speaker) from the HEPscreen project consortium
checked each language translation.
The survey was sent via email in July 2012. Two
further reminders were sent and the survey finally
closed in September 2012. The reminder schedule
conformed to the deadlines set out within our EU
Health Programme milestone framework (achievement
of which was a condition of our funding). Data were
anonymised, extracted and a descriptive analysis was
performed using SPSS 19.02. We calculated propor-
tions at the country level for both questions about
language support availability and about agreement
with language barriers as explanations. To account for
different numbers of respondents across each of the
five health services, we calculated a weighted average
by summing the proportions in each response cat-
egory in each survey and dividing by five.
Results
We received a total of 238 responses from 1026 recipi-
ents (23% response rate). The distribution across the six
countries was: 17 in Spain, 21 in Hungary, 42 in the UK,
49 in the Netherlands, 52 in Italy and 57 in Germany.
The total included representatives from each of the five
areas of health care in all six countries, 81% of whom
have a clinical role/are involved in the care of patients.
The health care professions/areas of expertise of the 238
respondents were as follows: 87 (37%) from antenatal
care, 64 (27%) specialists in gastroenterology/hepatology
or infectious diseases (in secondary care), 40 (17%) from
general practice/family medicine, 29 (12%) from sexual
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health/genito-urinary medicine, and 18 (8%) from health
care for asylum seekers and refugees.
Availability of language support
Of all six study countries, translated materials in lan-
guages other than the national language were most com-
monly available in the Netherlands and Germany where
just over one third (35 and 37%) indicated very common.
However, a large proportion (44 and 36% respectively)
indicated they were variably available (Table 1). Trans-
lated materials were least commonly available in Italy,
where 80% of respondents indicated ‘rarely or never’
along with the majority in Hungary (61%) and Spain
(60%). Half in the UK (51%) indicated translated mate-
rials were variably or not routinely available, with the
other half of respondents distributed in all of the other
response categories. Interpreters are also very com-
monly available in the Netherlands (60%), and in the
UK, where over half (54%) indicated very common and
no-one indicated rarely or never (also Table 1). In con-
trast, interpreters are rarely or never available for over
half in Italy (56%) and nearly half (45%) in Germany,
along with over a third in Hungary. Interpreters in
Spain seem to be more common than translated mate-
rials, which is a general trend seen in our data except
for in Germany where translated materials appear to be
more commonly available.
Language barriers as explanations
In the UK, over half agree or strongly agree that lan-
guage barriers explain all three scenarios (screening up-
take, screening offer and referral), and only a minority
(between 7 and 15%) expressed disagreement (Table 2).
Strongest agreement in the UK emerges about the role
of language barriers in referral, where nearly three quar-
ters (73%) strongly agree that these explain why cases do
not reach secondary care. A similar pattern emerges in
Germany, where three quarters of respondents agree/
strongly agree that language barriers are explanations.
Most agreement (over 75%) in Germany is seen for the
notion of language barriers as explanations of the lack of
screening by primary care services. A less conclusive
pattern is found in the Netherlands, where, although
between 40 and 55% agree that language barriers are
explanations of all three scenarios, a large proportion
are neutral and a significant minority disagree/strongly
disagree that language barriers explain the low uptake of
screening (33%) and why infected patients do not reach
secondary care (19%). An interestingly divergent pattern
is seen in Hungary, especially in response to language
barriers as explanations of low uptake and of why cases
do not reach secondary care. Whilst nearly half in
Hungary disagree/strongly disagree that language bar-
riers explain the low uptake of screening, over a third
agree/strongly agree that they do explain the low
screening uptake. Similarly, nearly half (44%) agree/
strongly agree that language barriers explain why
cases of chronic viral hepatitis do not reach specialist
care, one third in Hungary disagree/strongly disagree
with this notion. There is agreement (77%) that lan-
guage barriers explain why screening is not offered by
primary care services in Hungary. A similarly diver-
gent view is seen in Italy; 80% agree that language
barriers explain the lack of screening in primary care,
no such strong consensus emerges regarding the
other two issues. Although around half agree/strongly
agree that language barriers explain a low screening
uptake and why cases do not reach secondary care, a
significant minority disagree, especially so about the
lack of screening offer (26%). In Spain, there is also
some diversity in opinion although around two thirds
(68%) agree that language barriers are explanations of
the lack of screening in primary care and why hepa-
titis B/C cases do not reach secondary care. Variety
in perception of language barriers as explanations of
low screening uptake is seen, with 40% in agreement/
strong agreement and 33% in disagreement/strong
disagreement.
Discussion
European countries have differing historical experi-
ences of migration, with the six countries in our
study illustrative both of these differences and of the
availability services to overcome barriers to health
care, in this instance language barriers. Our first aim
was to understand availability of language support
(translated materials and interpreters) in health care
services most involved in screening and/or treating
Table 1 Availability of translated materials (TM) and interpreters (I) in the six countries
DE (n = 57) HU (n = 21) IT (n = 52) NL (n = 49) ES (n = 17) UK (n = 42)
TM I TM I TM I TM I TM I TM I
Very common 35% 10% 6% 14% 5% 2% 37% 60% 15% 25% 20% 54%
Variable or not routinely 36% 23% 16% 40% 13% 38% 44% 24% 20% 50% 51% 36%
Rarely or never 17% 45% 61% 36% 80% 56% 14% 10% 60% 23% 13% 0%
Unsure 12% 22% 17% 11% 2% 4% 6% 6% 5% 3% 17% 11%
Abbreviations: DE Germany, HU Hungary, IT Italy, NL the Netherlands, ES Spain, UK United Kingdom
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chronic hepatitis B/C among at risk migrant commu-
nities. Results suggest that translated materials are
rarely or never available in Hungary, Italy and Spain
but more commonly or variably available in the
Netherlands, Germany and the UK. Our results sug-
gest that interpreters are quite commonly available in
the UK, the Netherlands and Spain but more variably
or rarely available in Germany, Hungary and Italy.
Our second research aim was to investigate how far
professionals agree that language barriers explain
three scenarios: the low uptake of screening among
people with country of birth-related risk factors; the
lack of screening in primary care among these risk
groups; and why cases of chronic viral hepatitis do
not reach specialist care for clinical management and
treatment. Three interesting results emerge from this
second research question: one, that opinion about the
role of language barriers in the three scenarios is not
identical in each country; two, that differences of
opinion within one country about each scenario exist;
and three, that professionals in countries with the
most infrequent availability (Hungary and Italy) dis-
agree most that language barriers are explanations.
Our findings both mirror and contrast with those from
other studies about language support in health services
in these six study countries and about barriers to screen-
ing and referral for chronic viral hepatitis internationally.
In an analysis of migrant health policies, the provision of
interpreters was found to be detailed in policy goals in
the UK, the Netherlands and Spain although actual im-
plementation of policy was considered patchy [26],
which is what we see in our results for these three
countries. A summary study in Germany similarly found
that the use of interpreters in health care is not well-
established and that availability is the exception not the
rule [29], again in line with the variable or not routine
availability reported by 36% of respondents here. Other
studies from the Netherlands seem to suggest a less
frequent availability of support services than we see
reported in our study; studies found poor information
exchange between migrant patients and health care pro-
fessionals, an underreporting of poor Dutch proficiency
in medical records, that family members are used as in-
terpreters and that professional interpreter services are
hardly used in hospital settings [30, 31].
In the UK, the Netherlands and Germany, migration
from the former Empire (in the case of the UK) and
from the Mediterranean region (in the Netherlands and
Germany) has been an historic trend since the 1950s,
although war, conflict and economic crisis in the Eastern
Mediterranean region has led to an influx of migrants
presenting new challenges to health care systems. In
contrast, migration to Spain and Italy is a relatively new
phenomenon and it is only in the last two decades that
these countries have experienced migration in large
numbers from, for example, 2.5% in 2001 in Spain to
13.2% in 2012 [32]. Migration to Hungary is still rela-
tively uncommon with just 4.6% of the population
foreign-born in 2012 [23]. Given these differences in the
population of migrants, disagreement about the role that
language barriers play in screening and referral could be
explained by how likely it is that professionals encounter
linguistic minority patients in their services. Disagree-
ment about their role a could reflect a perception that
Table 2 Scale of agreement that language barriers explain three scenarios
Scenario Response option DE (n = 31) HU (n = 18) IT (n = 35) NL (n = 49) ES (n = 15) UK (n = 39)
Language barriers explain the low
uptake of screening by people with
country of birth-related risk factors
Strongly disagree 3% 18% 0% 2% 13% 3%
Disagree 10% 35% 26% 31% 20% 13%
Neutral 23% 12% 26% 22% 27% 23%
Agree 52% 24% 31% 39% 33% 54%
Strongly Agree 13% 12% 17% 6% 7% 8%
A lack of translated materials/interpreters
explains the lack of screening in primary care
Strongly disagree 0% 6% 0% 0% 0% 0%
Disagree 7% 6% 6% 14% 13% 15%
Neutral 16% 12% 14% 45% 27% 33%
Agree 68% 59% 63% 37% 53% 44%
Strongly Agree 10% 18% 17% 4% 7% 8%
Language barriers explain why hepatitis B/C
cases do not reach specialist secondary care
Strongly disagree 4% 22% 0% 0% 0% 0%
Disagree 13% 11% 15% 19% 18% 7%
Neutral 17% 22% 35% 26% 18% 20%
Agree 58% 33% 39% 41% 46% 63%
Strongly Agree 8% 11% 12% 15% 18% 10%
Abbreviations: DE Germany, HU Hungary, IT Italy, NL the Netherlands, ES Spain, UK United Kingdom
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people with country of birth-related risk factors are not
linguistic minorities (due to speaking the same/similar
languages) and/or can speak the national language to a
good enough standard not to require support. The re-
sults could also reflect underlying socio-cultural value
systems that migrants should assimilate and adapt by
learning the national language. Indeed, interpreters are
reported to be less common in the three ‘difference-
blind’ systems in our study, namely Germany (10%),
Hungary (14%) and Italy (2%) compared to the ‘differ-
ence-based’ systems of the UK (54%), the Netherlands
(60%) and Spain (25%). Agreement that language bar-
riers exist is however most strong in Germany, suggest-
ing that clinicians may not subscribe to the socio-
cultural value system of assimilation over adaptation.
Agreement in the Netherlands is surprisingly low across
the three scenarios, which could be explained either by
the common availability of interpreters we see in the
results from our first aim (and therefore removal of lan-
guage barriers) or by the socio-political shift from multi-
culturialist ‘difference-based’ policies to inter-culturalist
policies that favour individual responsibility and encour-
age migrants to learn Dutch [24]. A recent study from
the Netherlands offers some support for this notion and
found that whilst it is hospital policy to make (hospital-
funded) interpreters available, nursing service heads
rarely reference the policy, and health care providers in-
dicated that it is the responsibility of patients to over-
come language barriers by bringing an interpreter to
appointments [30]. Similarly, public funding for inter-
preters in health care was recently withdrawn [33]. Dis-
agreement about the role of language barriers in the
three scenarios could also reflect a perception of priori-
tisation i.e. that language barriers are not as important
explanations when compared to other factors such as
health care provider knowledge, awareness of country of
birth as a risk factor, or a lack of time in health care ap-
pointments [34]. A study from the US found that hepa-
titis C testing is rarely performed in primary care among
patients presenting with infection risk factors, although
the list in the study did not include birth in an endemic
country, itself an indication of the lack of awareness
about this important risk group [35]. Another study in
the US found frequent reports of communication bar-
riers between physicians and CHC patients, including
stigmatisation, assumptions of sexual promiscuity or
injecting drug use as the source of infection, a lack of
disease-related explanation or post-test counselling, and
an unwillingness to refer [36]. The finding that stigma-
tisation and assumptions are made about patients in-
fected with viral hepatitis, about people with the
additional barrier of language, increases the likelihood of
these patients receiving poor quality health care. A study
in Australia about barriers faced by migrants in
accessing health care for viral hepatitis infection found
that language barriers was the ‘chief barrier’ for 45% of
patients with a migrant background [8]. Studies from
the UK, the Netherlands and Italy show that a large pro-
portion of chronic viral hepatitis patients do not reach
secondary care [6, 9, 37, 38] and that immigration is
negatively associated with being on treatment [39, 40].
These studies suggest multiple explanations for why
screening isn’t offered to or taken up by at-risk migrant
groups as well as why diagnosed patients do not reach
specialist care. However, to realise the public health
gains possible due to improved treatment regimens,
screening and referral needs to be scaled up [41].
A strength of this study is the inclusion of study coun-
tries that reflect different models and value systems in
health care delivery. Previous multi-country research
among expert clinicians and policy makers about the
provision of hepatitis B/C screening and treatment services
for at risk populations has only been conducted in English
[42, 43]. The translation of our survey into the national
languages of our study countries is a concerted effort to
overcome language barriers, an important strength given
the focus of the study on language barriers themselves. A
further strength is the inclusion of experts across the
patient pathway, from primary to secondary care as well as
specific services for refugees and asylum seekers. It is no-
toriously challenging to yield high response rates to non-
incentivised online surveys among busy, practising clini-
cians. We reached 238 knowledgeable experts in five areas
of health care in the six countries and, although the overall
response rate is low (23%), the results in all six countries
are broadly in line with the scarce disease-specific, migrant
population-specific and European-focused research
available to compare and contrast our findings with.
Conclusions
Our findings show pronounced differences between
countries in the availability of interpreters, differences
that mirror the underlying socio-cultural value systems
of ‘difference-sensitive’ and ‘difference-blindness’ that
have been described in literature. Results also suggest
varying or service-/professional-specific availability of
interpreters and/or translated written materials for
chronic viral hepatitis. This is despite the complexity of
the disease, the recognised barriers to screening and
care, and the large undiagnosed burden among (poten-
tially) linguistic minority migrant groups. This finding is
mirrored in the view among many clinicians in the six
study countries that language barriers are important
explanations of low screening uptake, a lack of screening
by primary care, and why diagnosed hepatitis B/C pa-
tients do not reach secondary care. Europe is behind the
curve of viral hepatitis-related mortality and getting
ahead requires expanding and improving access to
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screening among at risk populations, especially among
people with country of birth-related risk factors. Evi-
dence shows that interpreters and translated materials
can improve acceptance of screening, patient knowledge
and understanding, and, most importantly, clinical out-
comes. To overcome language barriers, it is important
that existing and future screening programmes provide
language support for linguistic minority patients at risk
of or diagnosed with chronic viral hepatitis.
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